,Gene_set,Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes,cluster,ordered_cluster
0,KEGG_2021_Human,Neuroactive ligand-receptor interaction,15/341,1.043647397452382e-14,1.5237252002804777e-12,0,0,23.147711184521,745.2051365925187,GABBR2;VIPR1;ADCYAP1R1;CCK;HTR2A;AGT;C3;GRM3;ADCYAP1;GRM5;CCKBR;GRM7;SST;CRH;VIP,1,1
1,KEGG_2021_Human,Calcium signaling pathway,12/240,1.4871825959901125e-12,1.085643295072782e-10,0,0,24.709273182957396,672.9357473705566,FGF7;GRM5;CCKBR;FGF9;GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2;FGFR3,1,1
2,KEGG_2021_Human,Circadian entrainment,8/97,1.975782632037236e-10,9.615475475914548e-09,0,0,38.80214948705422,867.0296200628992,ADCYAP1;ADCYAP1R1;GNAS;GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
3,KEGG_2021_Human,cAMP signaling pathway,10/216,2.7701689206967847e-10,1.0111116560543266e-08,0,0,21.77846425419241,479.277413398441,GABBR2;ADCYAP1;ADCYAP1R1;SST;GNAS;CALM3;ADCY1;VIP;CALM1;CALM2,1,1
4,KEGG_2021_Human,Renin secretion,7/69,6.627052212973212e-10,1.9350992461881785e-08,0,0,47.76527110501029,1009.5042375995776,ADCYAP1;ADCYAP1R1;GNAS;CALM3;CALM1;CALM2;AGT,1,1
5,KEGG_2021_Human,Pathways in cancer,13/531,1.1527687336172388e-09,2.7607335017155757e-08,0,0,11.892080233543648,244.75208290639924,HSP90AA1;LAMA2;ADCY1;AGT;FGF7;FGF9;GNAS;GNB3;CALM3;ITGAV;CALM1;CALM2;FGFR3,1,1
6,KEGG_2021_Human,Gastric acid secretion,7/76,1.3236393501376044e-09,2.7607335017155757e-08,0,0,42.90440949737897,877.0897296081049,CCKBR;SST;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
7,KEGG_2021_Human,Vascular smooth muscle contraction,8/133,2.488011273086011e-09,4.54062057338197e-08,0,0,27.57704347826087,546.3503772110832,RAMP2;GNAS;CALM3;ADCY1;CALM1;CALM2;RAMP1;AGT,1,1
8,KEGG_2021_Human,Fluid shear stress and atherosclerosis,8/139,3.5311066224822603e-09,5.7282396320267786e-08,0,0,26.306007301692667,511.95842602033446,HSP90AA1;BMPR2;GPC1;SDC2;CALM3;ITGAV;CALM1;CALM2,1,1
9,KEGG_2021_Human,Rap1 signaling pathway,9/210,4.615446278133658e-09,6.73855156607514e-08,0,0,19.64676616915423,377.097225707356,FGF7;FGF9;GNAS;CALM3;ADCY1;CALM1;NGF;CALM2;FGFR3,1,1
10,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,7/98,8.005088723446983e-09,1.0624935942029632e-07,0,0,32.49590834697218,605.8273417710088,GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2,1,1
11,KEGG_2021_Human,Estrogen signaling pathway,7/137,8.212378823995972e-08,9.991727569195097e-07,0,0,22.70245499181669,370.3914185028143,GABBR2;HSP90AA1;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
12,KEGG_2021_Human,Phospholipase D signaling pathway,7/148,1.394804664522445e-07,1.5664729309252071e-06,0,0,20.919722347970424,330.2249565556344,GRM3;GRM5;GRM7;GNAS;FYN;ADCY1;AGT,1,1
13,KEGG_2021_Human,Human cytomegalovirus infection,8/225,1.510122982568582e-07,1.5748425389643786e-06,0,0,15.811660989781608,248.33643840956776,GNAS;GNB3;CALM3;ITGAV;CALR;ADCY1;CALM1;CALM2,1,1
14,KEGG_2021_Human,Ras signaling pathway,8/232,1.909307265771219e-07,1.858392405350653e-06,0,0,15.312111801242237,236.8991199689825,FGF7;FGF9;GNB3;CALM3;CALM1;NGF;CALM2;FGFR3,1,1
15,KEGG_2021_Human,Aldosterone synthesis and secretion,6/98,2.532060573247528e-07,2.3105052730883694e-06,0,0,26.97554347826087,409.7332084142577,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
16,KEGG_2021_Human,Glutamatergic synapse,6/114,6.207353827865036e-07,5.331021522754678e-06,0,0,22.96064814814815,328.16187122039463,GRM3;GRM5;GRM7;GNAS;GNB3;ADCY1,1,1
17,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,7.994057250720134e-07,6.484068658917442e-06,0,0,21.9391592920354,308.01257217083014,BEX3;MAGED1;CALM3;CALM1;NGF;CALM2,1,1
18,KEGG_2021_Human,Long-term potentiation,5/67,1.0094723525645732e-06,7.756998077601457e-06,0,0,32.725477287689266,451.8106486722008,GRM5;CALM3;ADCY1;CALM1;CALM2,1,1
19,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,3.0899152241317856e-06,2.2556381136162035e-05,0,0,17.18923611111111,218.08614532374077,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
20,KEGG_2021_Human,Insulin secretion,5/86,3.5017796057616127e-06,2.434570583053312e-05,0,0,25.025195263290502,314.3724904232026,ADCYAP1;ADCYAP1R1;GNAS;CCK;ADCY1,1,1
21,KEGG_2021_Human,PI3K-Akt signaling pathway,8/354,4.553897510211456e-06,3.022131984049421e-05,0,0,9.851721538074893,121.17151599998832,HSP90AA1;FGF7;LAMA2;FGF9;GNB3;ITGAV;NGF;FGFR3,1,1
22,KEGG_2021_Human,Salivary secretion,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
23,KEGG_2021_Human,GnRH signaling pathway,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
24,KEGG_2021_Human,Dilated cardiomyopathy,5/96,6.021867675296783e-06,3.5167707223733214e-05,0,0,22.26396052926665,267.6153236534291,LAMA2;GNAS;ITGAV;ADCY1;AGT,1,1
25,KEGG_2021_Human,Melanogenesis,5/101,7.724339574079212e-06,4.337513760829096e-05,0,0,21.09906462585034,248.3599218565523,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
26,KEGG_2021_Human,Alcoholism,6/186,1.0638466501721174e-05,5.752652256486265e-05,0,0,13.72638888888889,157.1813487493952,CRH;GNAS;GNB3;CALM3;CALM1;CALM2,1,1
27,KEGG_2021_Human,Dopaminergic synapse,5/132,2.831603443040529e-05,0.00014764789381568473,0,0,15.923991643901656,166.7573514553601,GNAS;GNB3;CALM3;CALM1;CALM2,1,1
28,KEGG_2021_Human,Apelin signaling pathway,5/137,3.3850551550368565e-05,0.0001704200181501314,0,0,15.316944959802102,157.66581943137734,GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
29,KEGG_2021_Human,Amphetamine addiction,4/69,3.602036909984236e-05,0.00017529912961923282,0,0,24.46892307692308,250.35197505624168,GNAS;CALM3;CALM1;CALM2,1,1
30,KEGG_2021_Human,Pertussis,4/76,5.271485603870497e-05,0.0002482699671500299,0,0,22.08222222222222,217.52343067641664,C3;CALM3;CALM1;CALM2,1,1
31,KEGG_2021_Human,Phototransduction,3/28,5.810403466594087e-05,0.0002617739640180578,0,0,46.87294117647059,457.1647065883405,CALM3;CALM1;CALM2,1,1
32,KEGG_2021_Human,Oxytocin signaling pathway,5/154,5.916808775750622e-05,0.0002617739640180578,0,0,13.55773181755924,131.98625761046438,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
33,KEGG_2021_Human,Gap junction,4/88,9.354594936602666e-05,0.0004016973119835262,0,0,18.91619047619048,175.48659250397716,GRM5;GNAS;ADCY1;HTR2A,1,1
34,KEGG_2021_Human,Morphine addiction,4/91,0.000106577031711311,0.0004445784751386116,0,0,18.26114942528736,167.02820601322307,GABBR2;GNAS;GNB3;ADCY1,1,1
35,KEGG_2021_Human,Chagas disease,4/102,0.0001657823674426373,0.0006723396012951402,0,0,16.202448979591836,141.03963960469565,C3;GNAS;CALR;ADCY1,1,1
36,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.00017122135089338915,0.0006756301954171573,0,0,10.72405557967868,93.00494455997634,C3;GNB3;CALM3;CALM1;CALM2,1,1
37,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.000199326791310776,0.0007658345139835076,0,0,15.412038834951456,131.31927733074235,GNAS;CALM3;CALM1;CALM2,1,1
38,KEGG_2021_Human,Serotonergic synapse,4/113,0.00024573837221964146,0.0009199436498478884,0,0,14.559266055045873,121.005599767331,APP;GNAS;GNB3;HTR2A,1,1
39,KEGG_2021_Human,Human immunodeficiency virus 1 infection,5/212,0.00026466355374569627,0.0009660219711717914,0,0,9.730355910480132,80.14943931431162,GNB3;CALM3;CALR;CALM1;CALM2,1,1
40,KEGG_2021_Human,Oocyte meiosis,4/129,0.000407000588894781,0.0014493191702106,0,0,12.68544,99.03137276252956,CALM3;ADCY1;CALM1;CALM2,1,1
41,KEGG_2021_Human,Chemical carcinogenesis,5/239,0.0004586521034758538,0.0015735975927782,0,0,8.595848595848596,66.07816703503416,HSP90AA1;FGF7;FGF9;GNAS;ADCY1,1,1
42,KEGG_2021_Human,Alzheimer disease,6/369,0.00046345682527030126,0.0015735975927782,0,0,6.743457300275482,51.76815497520017,APP;GRM5;CALM3;APOE;CALM1;CALM2,1,1
43,KEGG_2021_Human,Cortisol synthesis and secretion,3/65,0.0007219487708068914,0.0023955572849501,0,0,18.865275142314992,136.46303129351548,GNAS;ADCY1;AGT,1,1
44,KEGG_2021_Human,Cushing syndrome,4/155,0.0008119725925588695,0.0026343999669687,0,0,10.487417218543046,74.62892207334495,CRH;GNAS;ADCY1;AGT,1,1
45,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.001071387206826,0.0034004898303607,0,0,9.709447852760736,66.40098183251928,CALM3;ADCY1;CALM1;CALM2,1,1
46,KEGG_2021_Human,Glioma,3/75,0.0010950259740335,0.0034015700469979,0,0,16.236928104575163,110.68676861250448,CALM3;CALM1;CALM2,1,1
47,KEGG_2021_Human,Tuberculosis,4/180,0.0014128523783786,0.0042974259842351,0,0,8.986363636363636,58.96981810099653,C3;CALM3;CALM1;CALM2,1,1
48,KEGG_2021_Human,Axon guidance,4/182,0.0014713926415247,0.0043841495033187,0,0,8.884494382022472,57.9406383680362,BMPR2;FYN;SLIT2;L1CAM,1,1
49,KEGG_2021_Human,Pathways of neurodegeneration,6/475,0.0017113390889125,0.0049971101396246,0,0,5.191098081023454,33.06978194538061,APP;GRM5;CALM3;CALM1;CALM2;SPTBN2,1,1
50,KEGG_2021_Human,GABAergic synapse,3/89,0.0017932619219089,0.0051336517764451,0,0,13.584131326949384,85.9022295713123,GABBR2;GNB3;ADCY1,1,1
51,KEGG_2021_Human,Hypertrophic cardiomyopathy,3/90,0.001851578265349,0.0051986620527108,0,0,13.42731575388776,84.480869278287,LAMA2;ITGAV;AGT,1,1
52,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0022930908485876,0.006316816299883,0,0,12.423028785982478,75.50536334754598,CALM3;CALM1;CALM2,1,1
53,KEGG_2021_Human,Amoebiasis,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,LAMA2;GNAS;ADCY1,1,1
54,KEGG_2021_Human,Pancreatic secretion,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,GNAS;CCK;ADCY1,1,1
55,KEGG_2021_Human,Lipid and atherosclerosis,4/215,0.002697650323824,0.007033159772827,0,0,7.482464454976303,44.261576705232,HSP90AA1;CALM3;CALM1;CALM2,1,1
56,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0027948406111328,0.0071378709283004,0,0,11.557949912638325,67.96051664386877,CALM3;CALM1;CALM2,1,1
57,KEGG_2021_Human,Regulation of actin cytoskeleton,4/218,0.0028355925605576,0.0071378709283004,0,0,7.376448598130841,43.26659132198892,FGF7;FGF9;ITGAV;FGFR3,1,1
58,KEGG_2021_Human,Cholinergic synapse,3/113,0.003532603766938,0.0087416974571687,0,0,10.607486631016044,59.88690015339679,GNB3;FYN;ADCY1,1,1
59,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0040846356940378,0.0099392801888255,0,0,10.05578093306288,55.31205165088091,SST;GNAS;ADCY1,1,1
60,KEGG_2021_Human,Parkinson disease,4/249,0.0045546647346007,0.0107913140441421,0,0,6.432979591836735,34.68407434869999,GNAS;CALM3;CALM1;CALM2,1,1
61,KEGG_2021_Human,Platelet activation,3/124,0.0045826128132658,0.0107913140441421,0,0,9.637822070977151,51.90435545086567,GNAS;FYN;ADCY1,1,1
62,KEGG_2021_Human,Relaxin signaling pathway,3/129,0.0051158757030462,0.011855838930869,0,0,9.253034547152197,48.813520364788914,GNAS;GNB3;ADCY1,1,1
63,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0060441898254066,0.013788308039209,0,0,8.69710272168569,44.43052189846708,CALM3;CALM1;CALM2,1,1
64,KEGG_2021_Human,Cell adhesion molecules,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,SDC2;ITGAV;L1CAM,1,1
65,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,GRM5;GNB3;ADCY1,1,1
66,KEGG_2021_Human,Cocaine addiction,2/49,0.0077582958785982,0.0169061372876917,0,0,16.28396072013093,79.12364418473429,GRM3;GNAS,1,1
67,KEGG_2021_Human,Phagosome,3/152,0.0080417151800258,0.0172007183947057,0,0,7.815633636004738,37.69568331530969,C3;ITGAV;CALR,1,1
68,KEGG_2021_Human,MAPK signaling pathway,4/294,0.0081291066385937,0.0172007183947057,0,0,5.422344827586207,26.09397303713418,FGF7;FGF9;NGF;FGFR3,1,1
69,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0083825352441557,0.017483573509239,0,0,15.617739403453688,74.6778588702288,GNAS;ADCY1,1,1
70,KEGG_2021_Human,Cellular senescence,3/156,0.0086324665861653,0.0177512693180301,0,0,7.609765474817378,36.16331772907102,CALM3;CALM1;CALM2,1,1
71,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.0096962918823686,0.0196619252059142,0,0,14.436139332365748,66.92611152225938,GNAS;ADCY1,1,1
72,KEGG_2021_Human,Viral myocarditis,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,LAMA2;FYN,1,1
73,KEGG_2021_Human,Long-term depression,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,CRH;GNAS,1,1
74,KEGG_2021_Human,Melanoma,2/72,0.0162096794094039,0.0315548425836397,0,0,10.92087912087912,45.0174660560013,FGF7;FGF9,1,1
75,KEGG_2021_Human,Focal adhesion,3/201,0.0170388533623679,0.0327325340908647,0,0,5.8669043374925725,23.89155428844949,LAMA2;ITGAV;FYN,1,1
76,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0175083669365894,0.0331976827628838,0,0,10.47049525816649,42.35395328238597,GNAS;ADCY1,1,1
77,KEGG_2021_Human,Proteoglycans in cancer,3/205,0.0179464602548854,0.033592092271965,0,0,5.749563191613279,23.115327578724173,GPC1;SDC2;ITGAV,1,1
78,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,2/77,0.0183979906866827,0.0340013498766541,0,0,10.19025641025641,40.71531033833909,LAMA2;ITGAV,1,1
79,KEGG_2021_Human,Antigen processing and presentation,2/78,0.0188498685675458,0.0344010101357711,0,0,10.055668016194332,39.933564949004506,HSP90AA1;CALR,1,1
80,KEGG_2021_Human,Taste transduction,2/86,0.0226308480405061,0.040791405110048,0,0,9.094322344322345,34.453306781873835,GABBR2;GNB3,1,1
81,KEGG_2021_Human,ECM-receptor interaction,2/88,0.0236211971779791,0.0420572535120117,0,0,8.881932021466906,33.268260367425945,LAMA2;ITGAV,1,1
82,KEGG_2021_Human,Bile secretion,2/90,0.0246291595740698,0.0433235819013758,0,0,8.679195804195805,32.14621536477304,GNAS;ADCY1,1,1
83,KEGG_2021_Human,Small cell lung cancer,2/92,0.0256545239983583,0.0445900059971466,0,0,8.485470085470086,31.082576873519034,LAMA2;ITGAV,1,1
84,KEGG_2021_Human,TGF-beta signaling pathway,2/94,0.0266970809068837,0.0458561624988827,0,0,8.300167224080267,30.07317459219205,BMPR2;RGMB,1,1
0,KEGG_2021_Human,ECM-receptor interaction,27/88,3.121577620506939e-42,4.900876864195894e-40,0,0,121.9672131147541,11656.435266523007,ITGB1;LAMA5;LAMA2;SDC4;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;HSPG2;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;AGRN,2,2
1,KEGG_2021_Human,PI3K-Akt signaling pathway,31/354,2.005820378781639e-30,1.5745689973435868e-28,0,0,27.632398470224004,1889.5448462173244,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LPAR1;LAMC1;FGF1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;INSR;FN1;VEGFA;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2;FGFR3;FGFR2,2,2
2,KEGG_2021_Human,Focal adhesion,25/201,2.341937235769039e-28,1.2256138200524639e-26,0,0,37.86279176904177,2408.883976947515,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,2,2
3,KEGG_2021_Human,Human papillomavirus infection,27/331,1.3315421700310058e-25,5.226303017371698e-24,0,0,24.17393092105263,1384.641414326162,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;PSEN1;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;HLA-B;FN1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,2,2
4,KEGG_2021_Human,Amoebiasis,16/102,4.910489215498154e-20,1.5418936136664204e-18,0,0,44.41580274586719,1974.741171188804,LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;CD14,2,2
5,KEGG_2021_Human,Protein digestion and absorption,15/103,2.4886723577951323e-18,6.512026002897262e-17,0,0,40.204951298701296,1629.6989480841007,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL5A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,2,2
6,KEGG_2021_Human,Pathways in cancer,24/531,8.573607944232448e-17,1.9229377817778488e-15,0,0,12.240788954635107,452.8511447644845,ITGB1;LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LPAR1;FN1;LAMC1;FGF1;VEGFA;CXCL12;CDH1;COL4A1;COL4A5;ITGAV;IL6ST;CALM1;CALM2;FGFR3;FGFR2,2,2
7,KEGG_2021_Human,Small cell lung cancer,13/92,7.675496160151515e-16,1.5063161214297346e-14,0,0,37.92846629378864,1320.0368738297004,ITGB1;LAMA5;LAMA2;LAMB3;LAMC3;LAMA1;LAMB2;LAMA4;FN1;LAMC1;COL4A1;COL4A5;ITGAV,2,2
8,KEGG_2021_Human,Cell adhesion molecules,13/148,4.190032725026186e-13,7.309279309212345e-12,0,0,22.13247200689061,630.7953197363394,ITGB1;SDC4;SDC2;HLA-B;PTPRF;VCAN;CDH1;CNTN1;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,2,2
9,KEGG_2021_Human,Proteoglycans in cancer,13/205,2.6856812474675116e-11,4.216519558523992e-10,0,0,15.517017926356589,377.6919997211931,ITGB1;SDC4;LUM;SDC2;FN1;HSPG2;THBS1;VEGFA;COL1A1;COL1A2;PLAU;GPC1;ITGAV,2,2
10,KEGG_2021_Human,Axon guidance,12/182,1.039851627976818e-10,1.4841518690214583e-09,0,0,16.008924949290062,367.9935220603547,EFNA1;EPHB6;ITGB1;CXCL12;BMPR2;SEMA4D;SEMA4C;PLXNB2;PLXNB1;BMPR1B;BMP7;RGMA,2,2
11,KEGG_2021_Human,Toxoplasmosis,10/112,2.0696298276008702e-10,2.707765691111138e-09,0,0,21.8098700154219,486.3269757696262,ITGB1;LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LAMC1,2,2
12,KEGG_2021_Human,Rap1 signaling pathway,12/210,5.438491538701343e-10,6.568024396739313e-09,0,0,13.725531173807036,292.7978239304958,EFNA1;ITGB1;CDH1;INSR;LPAR1;CALM1;FGF1;CALM2;FGFR3;THBS1;FGFR2;VEGFA,2,2
13,KEGG_2021_Human,TGF-beta signaling pathway,8/94,2.120816277240928e-08,2.378343968048755e-07,0,0,20.25555839509328,357.8930243962554,BMPR2;TGFB3;BMPR1B;THBS1;BMP7;BMP6;RGMA;FBN1,2,2
14,KEGG_2021_Human,Fluid shear stress and atherosclerosis,9/139,2.970115395221404e-08,3.108720780331736e-07,0,0,15.208461538461538,263.59427112291235,BMPR2;SDC4;GPC1;SDC2;ITGAV;CALM1;BMPR1B;CALM2;VEGFA,2,2
15,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,8/100,3.460297182195935e-08,3.3954166100297613e-07,0,0,18.928810320114668,325.18420834985045,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5;VEGFA,2,2
16,KEGG_2021_Human,Regulation of actin cytoskeleton,9/218,1.3633702696693352e-06,1.2591125431652092e-05,0,0,9.422009569377993,127.24942872918471,ITGB1;CXCL12;LPAR1;FN1;ITGB8;ITGAV;FGF1;FGFR3;FGFR2,2,2
17,KEGG_2021_Human,Hypertrophic cardiomyopathy,6/90,5.618320831710298e-06,4.900424280991759e-05,0,0,15.220430107526882,184.0070507208982,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,2,2
18,KEGG_2021_Human,Dilated cardiomyopathy,6/96,8.168090042062541e-06,6.749421771599047e-05,0,0,14.201433691756272,166.3737075321738,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,2,2
19,KEGG_2021_Human,Phagosome,7/152,1.0577960784947751e-05,8.303699216183985e-05,0,0,10.36671664167916,118.76875537010444,ITGB1;CANX;HLA-B;ITGAV;CD14;THBS2;THBS1,2,2
20,KEGG_2021_Human,Hippo signaling pathway,7/163,1.666373293752292e-05,0.0001245812414852904,0,0,9.630365105908584,105.9559337246351,BMPR2;TGFB3;CDH1;FGF1;BMPR1B;BMP7;BMP6,2,2
21,KEGG_2021_Human,Ras signaling pathway,8/232,2.0079477150714128e-05,0.00014329445057555083,0,0,7.722527472527473,83.52540763828004,EFNA1;INSR;CALM1;FGF1;CALM2;FGFR3;FGFR2;VEGFA,2,2
22,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,5/77,3.999303234384312e-05,0.00027299591643405955,0,0,14.64908392434988,148.34842087800223,ITGB1;LAMA2;LAMA1;ITGB8;ITGAV,2,2
23,KEGG_2021_Human,Relaxin signaling pathway,6/129,4.39553949700668e-05,0.00028754154209585366,0,0,10.373983739837398,104.075282122445,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;VEGFA,2,2
24,KEGG_2021_Human,Bladder cancer,4/41,4.969531731284327e-05,0.0003120865927246557,0,0,22.60483641536273,224.00488351383737,CDH1;THBS1;FGFR3;VEGFA,2,2
25,KEGG_2021_Human,MAPK signaling pathway,8/294,0.00010667415032372514,0.0006124389871434357,0,0,6.029355260124491,55.14286549699501,EFNA1;TGFB3;INSR;CD14;FGF1;FGFR3;FGFR2;VEGFA,2,2
26,KEGG_2021_Human,Cytokine-cytokine receptor interaction,8/295,0.00010920558019729472,0.0006124389871434357,0,0,6.008040739748057,54.80702023799297,CXCL12;BMPR2;TGFB3;EBI3;IL6ST;BMPR1B;BMP7;BMP6,2,2
27,KEGG_2021_Human,Malaria,4/50,0.00010922478751602677,0.0006124389871434357,0,0,18.17391304347826,165.78429812678354,TGFB3;SDC2;THBS2;THBS1,2,2
28,KEGG_2021_Human,Pertussis,4/76,0.0005515183063396382,0.002985806003287,0,0,11.59590643274854,87.00217874091169,ITGB1;CD14;CALM1;CALM2,2,2
29,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,5/143,0.0007268380923843868,0.0038037860168116,0,0,7.617560900400863,55.05064100370834,BMPR2;IL6ST;BMPR1B;FGFR3;FGFR2,2,2
30,KEGG_2021_Human,Human cytomegalovirus infection,6/225,0.0008900120538199524,0.0045074804016042,0,0,5.798202975401384,40.728175403975015,CXCL12;HLA-B;ITGAV;CALM1;CALM2;VEGFA,2,2
31,KEGG_2021_Human,Calcium signaling pathway,6/240,0.0012407158303285,0.0060872620425492,0,0,5.4223876481941,36.28698026722881,CALM1;FGF1;CALM2;FGFR3;FGFR2;VEGFA,2,2
32,KEGG_2021_Human,Ovarian steroidogenesis,3/51,0.0020623100148981,0.0098115961314849,0,0,12.925130208333334,79.92808181101285,INSR;CGA;BMP6,2,2
33,KEGG_2021_Human,Alzheimer disease,7/369,0.0023943289322192,0.0110561659517181,0,0,4.106803987509008,24.783134057809825,APP;NCSTN;ADAM17;INSR;PSEN1;CALM1;CALM2,2,2
34,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.002731616757458,0.0122532523120261,0,0,5.57746717971933,32.92301698671435,HLA-B;IL6ST;CALM1;CALM2;VEGFA,2,2
35,KEGG_2021_Human,Notch signaling pathway,3/59,0.0031287815953977,0.013644964179929,0,0,11.07421875,63.866255600774856,ADAM17;NCSTN;PSEN1,2,2
36,KEGG_2021_Human,Viral myocarditis,3/60,0.0032817347324348,0.0136550169716428,0,0,10.87938596491228,62.2233763844449,LAMA2;LAMA1;HLA-B,2,2
37,KEGG_2021_Human,Platelet activation,4/124,0.003366483723708,0.0136550169716428,0,0,6.940701754385965,39.51956791413257,COL1A1;ITGB1;COL3A1;COL1A2,2,2
38,KEGG_2021_Human,Diabetic cardiomyopathy,5/203,0.0033920105853125,0.0136550169716428,0,0,5.293090479260692,30.09827210212563,COL1A1;COL3A1;COL1A2;TGFB3;INSR,2,2
39,KEGG_2021_Human,MicroRNAs in cancer,6/310,0.0044362006834023,0.0174120876823544,0,0,4.158955857385399,22.533043878755294,EFNA1;BMPR2;PLAU;FGFR3;THBS1;VEGFA,2,2
40,KEGG_2021_Human,Apelin signaling pathway,4/137,0.0048001024832091,0.0177671497879492,0,0,6.258171745152355,33.41311747814395,CDH1;SPP1;CALM1;CALM2,2,2
41,KEGG_2021_Human,Insulin signaling pathway,4/137,0.0048001024832091,0.0177671497879492,0,0,6.258171745152355,33.41311747814395,INSR;CALM1;CALM2;PTPRF,2,2
42,KEGG_2021_Human,Renin secretion,3/69,0.0048661620438332,0.0177671497879492,0,0,9.391571969696969,50.01434444725791,ADCYAP1R1;CALM1;CALM2,2,2
43,KEGG_2021_Human,Adherens junction,3/71,0.0052707201017753,0.0188068876358801,0,0,9.114430147058824,47.81054799529864,CDH1;INSR;PTPRF,2,2
44,KEGG_2021_Human,Gastric cancer,4/149,0.0064443661828935,0.0224836775714287,0,0,5.736769509981851,28.939414836750064,TGFB3;CDH1;FGF1;FGFR2,2,2
45,KEGG_2021_Human,Bacterial invasion of epithelial cells,3/77,0.006603441576186,0.0225378332056783,0,0,8.372888513513514,42.03327612835062,ITGB1;CDH1;FN1,2,2
46,KEGG_2021_Human,Cellular senescence,4/156,0.0075574728131978,0.0252451751419588,0,0,5.470637119113573,26.72525727072069,TGFB3;HLA-B;CALM1;CALM2,2,2
47,KEGG_2021_Human,Phototransduction,2/28,0.008431539185493,0.0275781594192166,0,0,15.761300555114987,75.2724399640349,CALM1;CALM2,2,2
48,KEGG_2021_Human,GnRH signaling pathway,3/93,0.0110683957301955,0.034754762592814,0,0,6.878819444444445,30.979874044611517,CGA;CALM1;CALM2,2,2
49,KEGG_2021_Human,Rheumatoid arthritis,3/93,0.0110683957301955,0.034754762592814,0,0,6.878819444444445,30.979874044611517,CXCL12;TGFB3;VEGFA,2,2
50,KEGG_2021_Human,Tuberculosis,4/180,0.0123136782089465,0.0374361505057287,0,0,4.7188995215311005,20.749211588141986,TGFB3;CD14;CALM1;CALM2,2,2
51,KEGG_2021_Human,Circadian entrainment,3/97,0.0123992345624069,0.0374361505057287,0,0,6.584773936170213,28.90795128943777,ADCYAP1R1;CALM1;CALM2,2,2
52,KEGG_2021_Human,Longevity regulating pathway,3/102,0.0141865718166554,0.0420243731172624,0,0,6.250631313131313,26.59930783049972,INSR;ADIPOQ;ADIPOR1,2,2
53,KEGG_2021_Human,NF-kappa B signaling pathway,3/104,0.0149403287857234,0.0434376225807145,0,0,6.126237623762377,25.75281052919957,CXCL12;PLAU;CD14,2,2
54,KEGG_2021_Human,HIF-1 signaling pathway,3/109,0.0169224556785904,0.0483059189370672,0,0,5.835790094339623,23.804851911614257,INSR;TIMP1;VEGFA,2,2
0,KEGG_2021_Human,ECM-receptor interaction,23/88,5.386567443540316e-39,5.1172390713633e-37,0,0,167.4029304029304,14751.02899936729,ITGB1;LAMA5;SDC4;LAMB2;LAMA4;FN1;LAMC1;THBS2;HSPG2;THBS1;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2;AGRN,3,3
1,KEGG_2021_Human,Focal adhesion,20/201,8.040215438571904e-25,3.819102333321655e-23,0,0,48.50583179864948,2691.111864328497,ITGB1;LAMA5;LAMB2;LAMA4;FN1;LAMC1;THBS2;THBS1;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2,3,3
2,KEGG_2021_Human,PI3K-Akt signaling pathway,23/354,2.8521578564809596e-24,9.031833212189704e-23,0,0,32.43360667529852,1758.3544619234665,ITGB1;LAMA5;LAMB2;LAMA4;FN1;LAMC1;FGF1;THBS2;THBS1;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2;FGFR2,3,3
3,KEGG_2021_Human,Human papillomavirus infection,22/331,2.061067024325773e-23,4.895034182773709e-22,0,0,32.49582298487243,1697.4593912718883,ITGB1;LAMA5;LAMB2;LAMA4;FN1;HLA-B;LAMC1;PSEN1;THBS2;THBS1;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2,3,3
4,KEGG_2021_Human,Protein digestion and absorption,14/103,1.81218232735761e-19,3.4431464219794592e-18,0,0,61.21260189469046,2641.604427995418,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2,3,3
5,KEGG_2021_Human,Amoebiasis,11/102,2.4851286764402372e-14,3.934787071030377e-13,0,0,44.42083842083842,1391.5212702893648,COL1A1;LAMA5;COL3A1;COL1A2;TGFB3;LAMB2;COL4A1;LAMA4;FN1;COL4A5;LAMC1,3,3
6,KEGG_2021_Human,Cell adhesion molecules,11/148,1.5895914294588225e-12,2.1573026542655447e-11,0,0,29.43741551770749,799.7422841296186,ITGB1;VCAN;SDC4;SDC2;CNTN1;HLA-B;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,3,3
7,KEGG_2021_Human,Small cell lung cancer,9/92,1.598363435638689e-11,1.8980565798209428e-10,0,0,38.43975903614458,955.5914895640896,ITGB1;LAMA5;LAMB2;COL4A1;LAMA4;FN1;COL4A5;ITGAV;LAMC1,3,3
8,KEGG_2021_Human,Proteoglycans in cancer,10/205,1.1261075746431996e-09,1.1886691065678218e-08,0,0,18.405594405594407,379.2380473797009,COL1A1;ITGB1;COL1A2;SDC4;LUM;SDC2;FN1;ITGAV;HSPG2;THBS1,3,3
9,KEGG_2021_Human,Axon guidance,9/182,7.236540758767754e-09,6.874713720829368e-08,0,0,18.35858794384806,344.1156220896642,EFNA1;EPHB6;ITGB1;BMPR2;SEMA4D;PLXNB2;PLXNB1;BMPR1B;RGMA,3,3
10,KEGG_2021_Human,TGF-beta signaling pathway,7/94,2.251223746923667e-08,1.9442386905249854e-07,0,0,27.53388822829964,484.8499314916691,BMPR2;TGFB3;BMPR1B;THBS1;BMP6;RGMA;FBN1,3,3
11,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,7/100,3.46734926038044e-08,2.744984831134515e-07,0,0,25.74972191323693,442.3104495763719,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5,3,3
12,KEGG_2021_Human,Pathways in cancer,12/531,1.2134667567866918e-07,8.867641684210439e-07,0,0,8.470280292289235,134.88594666453773,ITGB1;LAMA5;TGFB3;LAMB2;COL4A1;LAMA4;FN1;COL4A5;ITGAV;LAMC1;FGF1;FGFR2,3,3
13,KEGG_2021_Human,Toxoplasmosis,6/112,1.7010890323817115e-06,1.154310414830447e-05,0,0,19.023664854493123,252.7149658414067,ITGB1;LAMA5;TGFB3;LAMB2;LAMA4;LAMC1,3,3
14,KEGG_2021_Human,Phagosome,6/152,9.961227305355489e-06,6.30877729339181e-05,0,0,13.783840260041792,158.74587307419262,ITGB1;CANX;HLA-B;ITGAV;THBS2;THBS1,3,3
15,KEGG_2021_Human,Malaria,4/50,2.091019166526525e-05,0.00012415426301251242,0,0,28.352102637205988,305.5016709433986,TGFB3;SDC2;THBS2;THBS1,3,3
16,KEGG_2021_Human,Relaxin signaling pathway,5/129,6.256432242865122e-05,0.00034962415474834504,0,0,13.313844086021506,128.8688957167061,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5,3,3
17,KEGG_2021_Human,Regulation of actin cytoskeleton,6/218,7.565077172173232e-05,0.0003992679618646983,0,0,9.460984969619444,89.77890914462617,ITGB1;FN1;ITGB8;ITGAV;FGF1;FGFR2,3,3
18,KEGG_2021_Human,Fluid shear stress and atherosclerosis,5/139,8.914608920735945e-05,0.00044573044603679726,0,0,12.31405472636816,114.8314428240792,BMPR2;SDC4;SDC2;ITGAV;BMPR1B,3,3
19,KEGG_2021_Human,Hippo signaling pathway,5/163,0.00018823040863756807,0.0008940944410284486,0,0,10.43090717299578,89.47469208515557,BMPR2;TGFB3;BMPR1B;FGF1;BMP6,3,3
20,KEGG_2021_Human,Hypertrophic cardiomyopathy,4/90,0.0002104860778788391,0.0009521989237376056,0,0,15.134578726648876,128.13072143315782,ITGB1;TGFB3;ITGB8;ITGAV,3,3
21,KEGG_2021_Human,Dilated cardiomyopathy,4/96,0.00026968954146275857,0.0011645684744982,0,0,14.143264433357093,116.23272886658492,ITGB1;TGFB3;ITGB8;ITGAV,3,3
22,KEGG_2021_Human,Rap1 signaling pathway,5/210,0.0006027216803513163,0.0024895025927554,0,0,8.020325203252032,59.46313238394753,EFNA1;ITGB1;FGF1;THBS1;FGFR2,3,3
23,KEGG_2021_Human,Platelet activation,4/124,0.0007115764202639388,0.0028166566635447,0,0,10.827868852459016,78.48069379627387,COL1A1;ITGB1;COL3A1;COL1A2,3,3
24,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,3/77,0.0020189183674246,0.0076718897962135,0,0,12.986704446381866,80.58501236326349,ITGB1;ITGB8;ITGAV,3,3
25,KEGG_2021_Human,Diabetic cardiomyopathy,4/203,0.0043040567037926,0.0157263610330886,0,0,6.503336353900651,35.431459444238506,COL1A1;COL3A1;COL1A2;TGFB3,3,3
26,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,3/143,0.0113170631951042,0.0398192964272187,0,0,6.841589861751152,30.660199612393885,BMPR2;BMPR1B;FGFR2,3,3
27,KEGG_2021_Human,Gastric cancer,3/149,0.0126385131201869,0.04288066951492,0,0,6.558440123729563,28.666984607956127,TGFB3;FGF1;FGFR2,3,3
28,KEGG_2021_Human,MAPK signaling pathway,4/294,0.0153592322624334,0.0484117976077067,0,0,4.442057659694743,18.550203963470757,EFNA1;TGFB3;FGF1;FGFR2,3,3
29,KEGG_2021_Human,Cytokine-cytokine receptor interaction,4/295,0.0155331417223839,0.0484117976077067,0,0,4.426567517322968,18.435677040927693,BMPR2;TGFB3;BMPR1B;BMP6,3,3
30,KEGG_2021_Human,Notch signaling pathway,2/59,0.015797533956199,0.0484117976077067,0,0,11.071010860484543,45.92146177811471,NCSTN;PSEN1,3,3
0,KEGG_2021_Human,Axon guidance,16/182,6.143652096673225e-21,7.433819036974602e-19,0,0,54.47986230636833,2535.431097844656,EPHB6;SEMA4A;BMPR2;SEMA3A;L1CAM;RGMA;EFNB2;EFNA1;EFNA3;EFNB3;SLIT1;PLXNA2;PLXNB2;PLXNA1;PLXNB1;FYN,4,4
1,KEGG_2021_Human,Gastric acid secretion,8/76,1.6619950987241945e-11,1.0055070347281375e-09,0,0,54.39398084815321,1350.0813019282598,CHRM3;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,4,4
2,KEGG_2021_Human,cAMP signaling pathway,10/216,1.5213993016225158e-10,6.136310516544148e-09,0,0,23.375562396400664,528.4331161006214,AFDN;RYR2;BDNF;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,4,4
3,KEGG_2021_Human,Calcium signaling pathway,10/240,4.261440048805576e-10,1.2890856147636866e-08,0,0,20.910922587486745,451.1791635619605,CHRM3;NTRK2;RYR2;GRM5;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
4,KEGG_2021_Human,Rap1 signaling pathway,9/210,2.713239686625052e-09,6.566040041632625e-08,0,0,21.05330490405117,415.27901741432834,EFNA1;AFDN;EFNA3;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
5,KEGG_2021_Human,Ras signaling pathway,9/232,6.4860256675641745e-09,1.3080151762921086e-07,0,0,18.955156950672645,357.3732479355673,EFNA1;AFDN;NTRK2;EFNA3;BDNF;CALM3;CALM1;CALM2;FGFR2,4,4
6,KEGG_2021_Human,Salivary secretion,6/93,1.3063243917085897e-07,2.258075019953419e-06,0,0,30.439846743295018,482.4983051410993,CHRM3;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
7,KEGG_2021_Human,Circadian entrainment,6/97,1.6804872346961786e-07,2.54173694247797e-06,0,0,29.095970695970696,453.8683925156941,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
8,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,5.655858540441729e-07,7.603987593260548e-06,0,0,23.405309734513278,336.6948300317316,NTRK2;BEX3;BDNF;CALM3;CALM1;CALM2,4,4
9,KEGG_2021_Human,Long-term potentiation,5/67,7.556502457754822e-07,9.143367973883335e-06,0,0,34.86500701262272,491.4462332737665,GRM5;CALM3;ADCY1;CALM1;CALM2,4,4
10,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,2.194842311057381e-06,2.414326542163119e-05,0,0,18.33796296296296,238.9326611227857,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
11,KEGG_2021_Human,Oxytocin signaling pathway,6/154,2.557298478822763e-06,2.57860929947962e-05,0,0,17.838738738738737,229.70157432355884,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
12,KEGG_2021_Human,GnRH signaling pathway,5/93,3.868783762000668e-06,3.600944886169853e-05,0,0,24.531867588932805,305.7301262254058,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
13,KEGG_2021_Human,Aldosterone synthesis and secretion,5/98,5.007138045333038e-06,4.03909135656865e-05,0,0,23.20710612435717,283.23451619766166,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
14,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,5/98,5.007138045333038e-06,4.03909135656865e-05,0,0,23.20710612435717,283.23451619766166,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
15,KEGG_2021_Human,Melanogenesis,5/101,5.806669643086923e-06,4.391293917584486e-05,0,0,22.47848731884058,271.01195794624465,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
16,KEGG_2021_Human,Alcoholism,6/186,7.591650505747006e-06,5.403468889384633e-05,0,0,14.643703703703704,172.6267378009186,NTRK2;BDNF;GNAS;CALM3;CALM1;CALM2,4,4
17,KEGG_2021_Human,Glutamatergic synapse,5/114,1.0497195591783222e-05,7.056448147809833e-05,0,0,19.784603111288398,226.8186518465858,GRM5;GNAS;SLC17A7;ADCY1;SHANK1,4,4
18,KEGG_2021_Human,Vascular smooth muscle contraction,5/133,2.2160560400782075e-05,0.00013349805179754996,0,0,16.831691576086957,180.38854449241376,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
19,KEGG_2021_Human,Neuroactive ligand-receptor interaction,7/341,2.3934952288052774e-05,0.00013349805179754996,0,0,9.34301850843767,99.41131204948388,CHRM3;CORT;VIPR1;GRM5;SST;CHRNA4;SSTR2,4,4
20,KEGG_2021_Human,Pathways of neurodegeneration,8/475,2.478769818344427e-05,0.00013349805179754996,0,0,7.761366465813455,82.31055700707526,CHRM3;RYR2;GRM5;BDNF;CALM3;CALM1;CALM2;SPTBN2,4,4
21,KEGG_2021_Human,Apelin signaling pathway,5/137,2.556074640415341e-05,0.00013349805179754996,0,0,16.3183465085639,172.55758373501786,RYR2;CALM3;ADCY1;CALM1;CALM2,4,4
22,KEGG_2021_Human,Estrogen signaling pathway,5/137,2.556074640415341e-05,0.00013349805179754996,0,0,16.3183465085639,172.55758373501786,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
23,KEGG_2021_Human,Fluid shear stress and atherosclerosis,5/139,2.740612087918982e-05,0.00013349805179754996,0,0,16.073166774821544,168.84450512822406,BMPR2;GPC1;CALM3;CALM1;CALM2,4,4
24,KEGG_2021_Human,Amphetamine addiction,4/69,2.868553179120908e-05,0.00013349805179754996,0,0,26.03469721767594,272.2999619910236,GNAS;CALM3;CALM1;CALM2,4,4
25,KEGG_2021_Human,Renin secretion,4/69,2.868553179120908e-05,0.00013349805179754996,0,0,26.03469721767594,272.2999619910236,GNAS;CALM3;CALM1;CALM2,4,4
26,KEGG_2021_Human,Phospholipase D signaling pathway,5/148,3.702866760869487e-05,0.00016594328817229922,0,0,15.054727880814838,153.61570551961768,ARF1;GRM5;GNAS;FYN;ADCY1,4,4
27,KEGG_2021_Human,Alzheimer disease,7/369,3.9578734076575255e-05,0.0001710366722594859,0,0,8.608048719236564,87.26167160544453,CHRM3;GRM5;ADAM10;CALM3;APOE;CALM1;CALM2,4,4
28,KEGG_2021_Human,Phototransduction,3/28,4.892036785487742e-05,0.0002041160176013851,0,0,49.81,494.3800262044663,CALM3;CALM1;CALM2,4,4
29,KEGG_2021_Human,Insulin secretion,4/86,6.825078055362669e-05,0.00027527814823296096,0,0,20.61961598339388,197.78998958092387,CHRM3;RYR2;GNAS;ADCY1,4,4
30,KEGG_2021_Human,Pancreatic secretion,4/102,0.0001325437143235115,0.0005173480462304803,0,0,17.23925314806774,153.92236199865638,CHRM3;RYR2;GNAS;ADCY1,4,4
31,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.0001594572631095374,0.0006029477761329384,0,0,16.39826482131791,143.38207573637712,GNAS;CALM3;CALM1;CALM2,4,4
32,KEGG_2021_Human,Cholinergic synapse,4/113,0.00019672555098134784,0.0007213270202649421,0,0,15.490923287136445,132.19490665993504,CHRM3;CHRNA4;FYN;ADCY1,4,4
33,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",4/119,0.00023990497290512933,0.0008537794623976661,0,0,14.678260869565218,122.3472331202438,SST;GNAS;ADCY1;SSTR2,4,4
34,KEGG_2021_Human,Human cytomegalovirus infection,5/225,0.00026568316853071457,0.0009185046683490418,0,0,9.747529644268775,80.2534200870244,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
35,KEGG_2021_Human,Oocyte meiosis,4/129,0.0003264419862028404,0.0010972077869595,0,0,13.497191489361702,108.34544253042898,CALM3;ADCY1;CALM1;CALM2,4,4
36,KEGG_2021_Human,Dopaminergic synapse,4/132,0.00035626298267516605,0.0011650762406404,0,0,13.178856382978724,104.63802930927736,GNAS;CALM3;CALM1;CALM2,4,4
37,KEGG_2021_Human,Cell adhesion molecules,4/148,0.0005491437022377603,0.001703753537712,0,0,11.705082742316783,87.87181656756027,CNTN1;CNTN2;NCAM1;L1CAM,4,4
38,KEGG_2021_Human,Retrograde endocannabinoid signaling,4/148,0.0005491437022377603,0.001703753537712,0,0,11.705082742316783,87.87181656756027,RIMS1;GRM5;SLC17A7;ADCY1,4,4
39,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.000863187272534167,0.0026111414994158,0,0,10.330766218509334,72.88230449848443,CALM3;ADCY1;CALM1;CALM2,4,4
40,KEGG_2021_Human,MAPK signaling pathway,5/294,0.0008964062940188855,0.002645491745763,0,0,7.394313224010832,51.88675950890251,EFNA1;NTRK2;EFNA3;BDNF;FGFR2,4,4
41,KEGG_2021_Human,Glioma,3/75,0.000926798741435889,0.0026700630408033,0,0,17.25434027777778,120.50041514783926,CALM3;CALM1;CALM2,4,4
42,KEGG_2021_Human,Pertussis,3/76,0.0009631598881733862,0.0027102871271855,0,0,17.017123287671232,118.18887540441294,CALM3;CALM1;CALM2,4,4
43,KEGG_2021_Human,Gap junction,3/88,0.0014715123364968,0.0040466589253662,0,0,14.605882352941176,95.2517448144162,GRM5;GNAS;ADCY1,4,4
44,KEGG_2021_Human,TGF-beta signaling pathway,3/94,0.0017782858455118,0.0047816130512652,0,0,13.638736263736265,86.36191536485507,BMPR2;RGMB;RGMA,4,4
45,KEGG_2021_Human,Dilated cardiomyopathy,3/96,0.0018887419901292,0.0049682126262096,0,0,13.344086021505376,83.69202965543494,RYR2;GNAS;ADCY1,4,4
46,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0019455397883127,0.0050087300933157,0,0,13.201462765957446,82.40637964942252,CALM3;CALM1;CALM2,4,4
47,KEGG_2021_Human,PI3K-Akt signaling pathway,5/354,0.0020350809618085,0.0051300999245589,0,0,6.104397657904572,37.83029327695501,EFNA1;NTRK2;EFNA3;BDNF;FGFR2,4,4
48,KEGG_2021_Human,Pathways in cancer,6/531,0.0022266273954097,0.0054984064253994,0,0,4.933079365079365,30.127633885451427,GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
49,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0023730744285327,0.0057428401170493,0,0,12.282178217821782,74.22819075934467,CALM3;CALM1;CALM2,4,4
50,KEGG_2021_Human,Parkinson disease,4/249,0.0037049325325254,0.0087901340477565,0,0,6.844637429439861,38.31689792331356,GNAS;CALM3;CALM1;CALM2,4,4
51,KEGG_2021_Human,Platelet activation,3/124,0.0038996254037596,0.0090741283433638,0,0,10.241735537190085,56.80962456263433,GNAS;FYN;ADCY1,4,4
52,KEGG_2021_Human,Nicotine addiction,2/40,0.0046740595984819,0.010670966253138,0,0,21.386680988184747,114.75509786105276,CHRNA4;SLC17A7,4,4
53,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0051507016536939,0.0115413870388327,0,0,9.242070895522389,48.69298109698855,CALM3;CALM1;CALM2,4,4
54,KEGG_2021_Human,Cocaine addiction,2/49,0.0069448554030986,0.015278681886817,0,0,17.283543204515848,85.89496010554357,BDNF;GNAS,4,4
55,KEGG_2021_Human,Vibrio cholerae infection,2/50,0.0072225026271421,0.0156057646050749,0,0,16.922619047619047,83.43788300609687,ARF1;GNAS,4,4
56,KEGG_2021_Human,Cellular senescence,3/156,0.0073716338926862,0.0156485561581584,0,0,8.086601307189543,39.70614967382036,CALM3;CALM1;CALM2,4,4
57,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0075051203009533,0.0156572337312991,0,0,16.576426488962934,81.09469280568841,GNAS;ADCY1,4,4
58,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.0086847744196851,0.0178111475386763,0,0,15.322294955718135,72.72242891249378,GNAS;ADCY1,4,4
59,KEGG_2021_Human,Tuberculosis,3/180,0.01087971815415,0.0219407649442025,0,0,6.981638418079096,31.5629745514898,CALM3;CALM1;CALM2,4,4
60,KEGG_2021_Human,Cortisol synthesis and secretion,2/65,0.0119692083073164,0.0237422000850048,0,0,12.8837058632977,57.01578256302679,GNAS;ADCY1,4,4
61,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,3/193,0.013120566714187,0.0256062672970424,0,0,6.499671052631579,28.16680744331868,CALM3;CALM1;CALM2,4,4
62,KEGG_2021_Human,Adherens junction,2/71,0.0141617305863652,0.0271995143007966,0,0,11.75983436853002,50.06410777572769,AFDN;FYN,4,4
63,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0157125715616093,0.0297065806086677,0,0,11.113223371540396,46.1564856237522,GNAS;ADCY1,4,4
64,KEGG_2021_Human,Human immunodeficiency virus 1 infection,3/212,0.0168379218668381,0.0310225932434209,0,0,5.90311004784689,24.109019739798107,CALM3;CALM1;CALM2,4,4
65,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0169214144964114,0.0310225932434209,0,0,10.672932330827068,43.53676225433978,RIMS1;SLC17A7,4,4
66,KEGG_2021_Human,Lipid and atherosclerosis,3/215,0.0174734371816651,0.0315565059549475,0,0,5.818691037735849,23.548669875985063,CALM3;CALM1;CALM2,4,4
67,KEGG_2021_Human,Bile secretion,2/90,0.0221351857372417,0.0393876099147978,0,0,9.211966604823749,35.1029985464868,GNAS;ADCY1,4,4
68,KEGG_2021_Human,Morphine addiction,2/91,0.0225961945539436,0.0396252107395244,0,0,9.108002751662465,34.51909152088551,GNAS;ADCY1,4,4
69,KEGG_2021_Human,Chemical carcinogenesis,3/239,0.0230387531768434,0.0398241304914007,0,0,5.220603813559322,19.68469159013861,CHRNA4;GNAS;ADCY1,4,4
70,KEGG_2021_Human,Amoebiasis,2/102,0.0279247580309207,0.0469291072464084,0,0,8.101632653061225,28.989598979218883,GNAS;ADCY1,4,4
71,KEGG_2021_Human,Chagas disease,2/102,0.0279247580309207,0.0469291072464084,0,0,8.101632653061225,28.989598979218883,GNAS;ADCY1,4,4
72,KEGG_2021_Human,"Parathyroid hormone synthesis, secretion and action",2/106,0.0299759378394035,0.049686143542025,0,0,7.788461538461538,27.31694072931825,GNAS;ADCY1,4,4
0,KEGG_2021_Human,Gastric acid secretion,7/76,4.271054034501409e-11,3.509635923240077e-09,0,0,74.76060118089103,1785.0271295248488,CCKBR;SST;CALM3;SSTR2;CALM1;CALM2;GNAI2,5,5
1,KEGG_2021_Human,cAMP signaling pathway,9/216,7.019271846480155e-11,3.509635923240077e-09,0,0,34.36347826086956,803.410442733645,AFDN;RYR2;CHRM1;SST;CALM3;SSTR2;CALM1;CALM2;GNAI2,5,5
2,KEGG_2021_Human,Axon guidance,7/182,2.0121135246007983e-08,6.70704508200266e-07,0,0,29.32,519.5942354391702,EPHB6;EFNB2;EFNA3;EFNB3;SLIT1;EFNA5;GNAI2,5,5
3,KEGG_2021_Human,Rap1 signaling pathway,7/210,5.3837168527674026e-08,1.3459292131918503e-06,0,0,25.24010217113665,422.4512060748127,AFDN;EFNA3;CALM3;CALM1;EFNA5;CALM2;GNAI2,5,5
4,KEGG_2021_Human,Neuroactive ligand-receptor interaction,8/341,8.115678987234583e-08,1.6231357974469163e-06,0,0,18.14091014091014,296.18451513190706,CORT;CHRM1;CCKBR;GRM7;SST;CCK;HTR2A;SSTR2,5,5
5,KEGG_2021_Human,Calcium signaling pathway,7/240,1.339919537207609e-07,2.233199228679348e-06,0,0,21.956922587823875,347.4789728974849,RYR2;CHRM1;CCKBR;CALM3;HTR2A;CALM1;CALM2,5,5
6,KEGG_2021_Human,Circadian entrainment,5/97,6.018775532874944e-07,8.598250761249921e-06,0,0,37.24512743628186,533.4698492415318,RYR2;CALM3;CALM1;CALM2;GNAI2,5,5
7,KEGG_2021_Human,Ras signaling pathway,6/232,2.3404406145870254e-06,2.9255507682337816e-05,0,0,18.716814159292035,242.66670269174864,AFDN;EFNA3;CALM3;CALM1;EFNA5;CALM2,5,5
8,KEGG_2021_Human,Apelin signaling pathway,5/137,3.32401706639395e-06,3.693352295993278e-05,0,0,25.90647857889237,326.7930395337648,RYR2;CALM3;CALM1;CALM2;GNAI2,5,5
9,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,5/150,5.181916041112465e-06,4.910448055180626e-05,0,0,23.56837098692033,286.83498629397224,RYR2;CALM3;CALM1;CALM2;GNAI2,5,5
10,KEGG_2021_Human,Renin secretion,4/69,5.563613593606419e-06,4.910448055180626e-05,0,0,40.8225641025641,493.9229285486092,CALM3;CALM1;CALM2;GNAI2,5,5
11,KEGG_2021_Human,Oxytocin signaling pathway,5/154,5.892537666216751e-06,4.910448055180626e-05,0,0,22.93103448275862,276.1314770207239,RYR2;CALM3;CALM1;CALM2;GNAI2,5,5
12,KEGG_2021_Human,Pertussis,4/76,8.187716397234901e-06,6.298243382488385e-05,0,0,36.84074074074074,431.5110106245045,CALM3;CALM1;CALM2;GNAI2,5,5
13,KEGG_2021_Human,Pathways of neurodegeneration,7/475,1.2584050854785217e-05,8.988607753418011e-05,0,0,10.80136119025008,121.872626209664,APP;RYR2;CHRM1;CALM3;CALM1;CALM2;SPTBN2,5,5
14,KEGG_2021_Human,Phototransduction,3/28,1.428271053604545e-05,9.5218070240303e-05,0,0,77.19096774193548,861.178006160516,CALM3;CALM1;CALM2,5,5
15,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,4/98,2.2452505027465568e-05,0.0001403281564216598,0,0,28.187234042553197,301.7192077711716,CALM3;HTR2A;CALM1;CALM2,5,5
16,KEGG_2021_Human,Melanogenesis,4/101,2.5286690488726575e-05,0.00014874523816897989,0,0,27.31134020618557,289.0968823719555,CALM3;CALM1;CALM2;GNAI2,5,5
17,KEGG_2021_Human,Dopaminergic synapse,4/132,7.210087243838666e-05,0.0003907761413653706,0,0,20.664583333333333,197.0873148667648,CALM3;CALM1;CALM2;GNAI2,5,5
18,KEGG_2021_Human,Vascular smooth muscle contraction,4/133,7.424746685942041e-05,0.0003907761413653706,0,0,20.50335917312661,194.94813077048929,CALM3;CALM1;CALM2;RAMP1,5,5
19,KEGG_2021_Human,Estrogen signaling pathway,4/137,8.330216171755053e-05,0.0004165108085877527,0,0,19.88270676691729,186.75898159502256,CALM3;CALM1;CALM2;GNAI2,5,5
20,KEGG_2021_Human,Fluid shear stress and atherosclerosis,4/139,8.811909401189984e-05,0.0004196147333899992,0,0,19.58617283950617,182.8725960938364,GPC1;CALM3;CALM1;CALM2,5,5
21,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.00017885007846034598,0.0008129549020924818,0,0,16.19877300613497,139.77860730352796,CALM3;CALM1;CALM2;GNAI2,5,5
22,KEGG_2021_Human,Long-term potentiation,3/67,0.00019961224115404484,0.0008678793093654123,0,0,30.09375,256.37268482629224,CALM3;CALM1;CALM2,5,5
23,KEGG_2021_Human,Amphetamine addiction,3/69,0.00021781120976074915,0.0009075467073364548,0,0,29.17888563049853,246.0329170453741,CALM3;CALM1;CALM2,5,5
24,KEGG_2021_Human,Alcoholism,4/186,0.0002700220709464343,0.0010721791694968,0,0,14.493772893772894,119.09543126730652,CALM3;CALM1;CALM2;GNAI2,5,5
25,KEGG_2021_Human,Glioma,3/75,0.0002787665840691884,0.0010721791694968,0,0,26.73924731182796,218.86436890068785,CALM3;CALM1;CALM2,5,5
26,KEGG_2021_Human,Alzheimer disease,5/369,0.0003727331437311914,0.0013804931249303,0,0,9.28476695718075,73.29996528011212,APP;CHRM1;CALM3;CALM1;CALM2,5,5
27,KEGG_2021_Human,Human immunodeficiency virus 1 infection,4/212,0.000443504253418508,0.0015839437622089,0,0,12.665384615384616,97.78694163313055,CALM3;CALM1;CALM2;GNAI2,5,5
28,KEGG_2021_Human,Lipid and atherosclerosis,4/215,0.0004676495230496821,0.0016125845622402,0,0,12.483412322274882,95.72020195912393,RXRA;CALM3;CALM1;CALM2,5,5
29,KEGG_2021_Human,Salivary secretion,3/93,0.000524654353740388,0.0016924333991625,0,0,21.372043010752687,161.41814422645928,CALM3;CALM1;CALM2,5,5
30,KEGG_2021_Human,GnRH signaling pathway,3/93,0.000524654353740388,0.0016924333991625,0,0,21.372043010752687,161.41814422645928,CALM3;CALM1;CALM2,5,5
31,KEGG_2021_Human,Human cytomegalovirus infection,4/225,0.0005549296578796657,0.0017341551808739,0,0,11.912518853695325,89.30421312308533,CALM3;CALM1;CALM2;GNAI2,5,5
32,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0005933546364116634,0.0017980443527626,0,0,20.45847632120796,152.00071591228536,CALM3;CALM1;CALM2,5,5
33,KEGG_2021_Human,Aldosterone synthesis and secretion,3/98,0.00061138323017245,0.0017981859710954,0,0,20.242105263157896,149.787258825716,CALM3;CALM1;CALM2,5,5
34,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0007269355198078752,0.0020769586280225,0,0,19.033854998403065,137.5514417752364,CALM3;CALM1;CALM2,5,5
35,KEGG_2021_Human,Glucagon signaling pathway,3/107,0.0007895773777299936,0.0021915219087462,0,0,18.482009925558312,132.0357140094594,CALM3;CALM1;CALM2,5,5
36,KEGG_2021_Human,Parkinson disease,4/249,0.0008108631062360987,0.0021915219087462,0,0,10.732517006802722,76.38773797570266,CALM3;CALM1;CALM2;GNAI2,5,5
37,KEGG_2021_Human,Serotonergic synapse,3/113,0.0009249471790851068,0.0024329390127198,0,0,17.468621700879766,122.03184199721754,APP;HTR2A;GNAI2,5,5
38,KEGG_2021_Human,Glutamatergic synapse,3/114,0.0009488462149607304,0.0024329390127198,0,0,17.310374891020054,120.4847761001414,GRM7;SLC17A7;GNAI2,5,5
39,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0010742237888164,0.0026200580215036,0,0,16.560066740823135,113.20721509642836,SST;SSTR2;GNAI2,5,5
40,KEGG_2021_Human,Neurotrophin signaling pathway,3/119,0.0010742237888164,0.0026200580215036,0,0,16.560066740823135,113.20721509642836,CALM3;CALM1;CALM2,5,5
41,KEGG_2021_Human,Oocyte meiosis,3/129,0.0013553632092342,0.0032270552600814,0,0,15.238095238095235,100.62759328722868,CALM3;CALM1;CALM2,5,5
42,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0016107379396855,0.0037459021853152,0,0,14.32258064516129,92.10941640869986,CALM3;CALM1;CALM2,5,5
43,KEGG_2021_Human,Pathways in cancer,5/531,0.0019057822111298,0.0043313232071132,0,0,6.372099121541891,39.90758219679386,RXRA;CALM3;CALM1;CALM2;GNAI2,5,5
44,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0020083403688533,0.0044629785974518,0,0,13.228698553948831,82.15612575990296,RIMS1;SLC17A7;GNAI2,5,5
45,KEGG_2021_Human,Cellular senescence,3/156,0.0023327324928401,0.0050711575931308,0,0,12.531941808981657,75.95252713466711,CALM3;CALM1;CALM2,5,5
46,KEGG_2021_Human,PI3K-Akt signaling pathway,4/354,0.0029425128713717,0.0062606656837696,0,0,7.472761904761905,43.55492808172386,EFNA3;CHRM1;RXRA;EFNA5,5,5
47,KEGG_2021_Human,Tuberculosis,3/180,0.003494532954702,0.0072802769889625,0,0,10.81957353745216,61.20151868394914,CALM3;CALM1;CALM2,5,5
48,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,3/193,0.0042483147656038,0.0086700301338854,0,0,10.072665534804754,55.00917241363458,CALM3;CALM1;CALM2,5,5
49,KEGG_2021_Human,PPAR signaling pathway,2/74,0.0070180079073391,0.0140360158146783,0,0,17.26909722222222,85.64221723890843,RXRA;FABP5,5,5
50,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0077696949613526,0.0152346960026521,0,0,16.356907894736842,79.45407878009898,RIMS1;SLC17A7,5,5
51,KEGG_2021_Human,Insulin secretion,2/86,0.0093768492240238,0.0180324023538921,0,0,14.793154761904765,69.07680592717206,RYR2;CCK,5,5
52,KEGG_2021_Human,Gap junction,2/88,0.0097999117683402,0.018490399562906,0,0,14.44767441860465,66.82601170344869,HTR2A;GNAI2,5,5
53,KEGG_2021_Human,Pancreatic secretion,2/102,0.0129930685283717,0.0240612380155031,0,0,12.41625,53.9279860105189,RYR2;CCK,5,5
54,KEGG_2021_Human,"Parathyroid hormone synthesis, secretion and action",2/106,0.0139781549967819,0.0254148272668763,0,0,11.936298076923077,50.971090560576506,RXRA;GNAI2,5,5
55,KEGG_2021_Human,Cholinergic synapse,2/113,0.0157775957885995,0.0281445537289251,0,0,11.179617117117116,46.38606860239311,CHRM1;GNAI2,5,5
56,KEGG_2021_Human,Leukocyte transendothelial migration,2/114,0.0160423956254873,0.0281445537289251,0,0,11.079241071428571,45.78518901835009,AFDN;GNAI2,5,5
